How should metabolic acidosis be corrected in a patient with acute kidney injury?

Management of Metabolic Acidosis in Acute Kidney Injury

The role of sodium bicarbonate for correcting metabolic acidosis in AKI remains uncertain and should be reserved for severe acidosis (pH <7.15) or used as part of renal replacement therapy (RRT) with bicarbonate-buffered dialysate, rather than as routine intravenous therapy.

Current Evidence and Guideline Framework

The 2020 KDIGO conference explicitly identified the role of sodium bicarbonate in AKI with metabolic acidosis as a research gap requiring further investigation 1. This acknowledgment reflects the lack of high-quality evidence supporting its routine use.

The most relevant clinical guidance comes from the 2017 Surviving Sepsis Campaign, which recommends against using sodium bicarbonate therapy to improve hemodynamics or reduce vasopressor requirements in patients with hypoperfusion-induced lactic acidemia when pH ≥ 7.15 (weak recommendation, moderate quality evidence) 2. While this addresses sepsis-related acidosis specifically, it provides the clearest threshold for clinical decision-making in critically ill patients with AKI.

Practical Management Algorithm

Step 1: Identify the Severity and Type of Acidosis

• pH ≥ 7.15: Avoid sodium bicarbonate administration for hemodynamic purposes 2
• pH < 7.15: Consider sodium bicarbonate or RRT initiation based on clinical context
• Assess chloride levels: Recent pediatric data suggests baseline chloride critically influences outcomes 3
  • Hyperchloremia (Cl ≥113 mmol/L): Sodium bicarbonate may be beneficial
  • Hypochloremia (Cl <107 mmol/L): Sodium bicarbonate associated with increased mortality
  • Normal chloride (107-113 mmol/L): Uncertain benefit

Step 2: Address Underlying Causes

• Avoid hyperchloremic fluids: Use balanced crystalloid solutions rather than 0.9% saline 1, 4
• Discontinue nephrotoxic medications that may be contributing to AKI 5
• Optimize hemodynamics with fluid resuscitation and vasopressors as needed 6

Step 3: Consider Renal Replacement Therapy

When metabolic acidosis is severe or refractory, RRT is the preferred intervention rather than intravenous sodium bicarbonate 7, 4:

• Use bicarbonate-buffered dialysate/replacement fluid rather than lactate-buffered solutions 8
  • Strong recommendation (1B) for patients with circulatory shock 8
  • Suggested (2B) for patients with liver failure or lactic acidemia 8
• Continuous RRT (CRRT) is preferred for hemodynamically unstable patients 2, 8
• Effluent dose: 20-25 mL/kg/h for CRRT 8

Step 4: Monitor and Reassess

• Serial arterial blood gases to track pH trends
• Monitor serum bicarbonate, chloride, and electrolytes
• Assess for complications of sodium bicarbonate (if used): volume overload, hypernatremia, hyperosmolarity 9

Critical Caveats and Pitfalls

The evidence for sodium bicarbonate is weak and potentially harmful 9, 10, 11. Recent research demonstrates that:

1. Sodium bicarbonate transiently corrects blood pH but has minimal effect on intracellular pH, which is the actual determinant of cellular function 9

2. The sodium load from bicarbonate infusion can worsen volume overload and increase osmolarity, potentially harming cellular function 9

3. Baseline chloride levels matter: In patients with hypochloremia, sodium bicarbonate may increase mortality 3

4. No mortality benefit has been demonstrated in most clinical scenarios, even in moderate-to-severe AKI 3

When Sodium Bicarbonate May Be Considered

Despite limited evidence, sodium bicarbonate administration may be reasonable in highly selected circumstances:

• Severe acidemia (pH <7.15) with hemodynamic instability when RRT is not immediately available
• Hyperchloremic metabolic acidosis (Cl ≥113 mmol/L) in AKI 3
• As a temporizing measure while arranging urgent RRT for life-threatening acidosis

Avoid sodium bicarbonate in:

• pH ≥ 7.15 2
• Hypochloremia (Cl <107 mmol/L) 3
• Volume-overloaded patients
• When RRT is readily available and appropriate

The Bottom Line

Prioritize RRT with bicarbonate-buffered solutions over intravenous sodium bicarbonate for managing metabolic acidosis in AKI 8, 7. The evidence supporting routine sodium bicarbonate administration is insufficient, and potential harms include volume overload, hyperosmolarity, and paradoxical worsening of intracellular acidosis 9. The 2020 KDIGO conference's identification of this as a research priority underscores the need for caution in clinical practice 1.